Sweden
· Delayed Price · Currency is SEK FluoGuide Company Description
FluoGuide A/S, a clinical stage biotechnology company, focused on developing drugs for surgical outcomes by making cancer fluorescent in Denmark.
Its lead product candidate is FG001, which is in Phase IIa and IIb for the treatment of high-grade glioma; Phase II clinical trial for the treatment of lung cancer, and head and neck cancer.
The company also develops FG002, which is in preclinical stage that allows surgeons to differentiate cancer from normal tissue during surgery through a novel uPAR-targeted luminescent technology.
It has an agreement with Linköping University Hospital for the development of FG001 that is in the Phase I/II clinical trial for surgical removal of brain cancer; collaboration with Copenhagen University Hospital; collaboration with Intuitive Surgical, Inc. for robotics surgery in head and neck cancer.
FluoGuide A/S was incorporated in 2018 and is headquartered in Copenhagen, Denmark.
| Country | Denmark |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Morten Albrechtsen |
Contact Details
Address: Ole MaalOees Vej 3 Copenhagen, 2200 Denmark | |
| Phone | 45 31 22 66 60 |
| Website | fluoguide.com |
Stock Details
| Ticker Symbol | FLUO |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | DKK |
| ISIN Number | DK0061123312 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Morten Albrechtsen B.B.A., BBA, M.D. | Chief Executive Officer |
| Ole Larsen Cand. merc., M.Sc. | Chief Financial Officer |
| Prof. Andreas Kjaer M.D., M.Sc., Ph.D. | CSO, Head of Scientific Advisory Board and Director |
| Dr. Grethe Nørskov Rasmussen M.Sc., Ph.D. | Chief Development Officer |
| Dorthe Gronnegaard Mejer | Vice President of Clinical Development |